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Abstract. Heat shock protein 27 (HSP27) is a member of the 
heat shock protein family which has been linked to tumour 
progression and, most interestingly, to chemotherapy resis-
tance in cancer patients. The present study examined the 
potential interplay between HSP27 and YangZheng XiaoJi, a 
traditional Chinese medicine used in cancer treatment. A range 
of cell lines from different tumour types including pancre-
atic, lung, gastric, colorectal, breast, prostate and ovarian 
cancer (both wild-type and resistant) were used. Levels and 
activation of HSP27 and its potential associated signalling 
pathways were evaluated by protein array and western blot-
ting. Knockdown of HSP27 in cancer cells was achieved using 
siRNA. Localisation and co-localisation of HSP27 and other 
proteins were carried out by immunofluorescence. Cell growth 
and migration were evaluated in their response to a range of 
chemotherapeutic agents. The present study first identified, by 
way of protein array, that YangZheng XiaoJi was able to inhibit 
the phosphorylation of HSP27 protein in cancer cells. We 
further demonstrated that HSP27, which is co-localised with 
caspase-9, can be blocked from localising in focal adhesions 
and co-localising with caspase-9 by YangZheng XiaoJi. The 
study also demonstrated that YangZheng XiaoJi was able to 
sensitise cancer cells including those cells that were resistant to 
chemotherapy, to chemotherapeutic agents. Finally, knocking 
down HSP27 markedly reduced the migration of cancer cells 
and increased the sensitivity of cancer cells to the inhibitory 
effect on cellular migration by YangZheng XiaoJi. YangZheng 
XiaoJi can act as an agent in first sensitising cancer cells to 
chemotherapy and secondly to overcome, to some degree, 
chemoresistance when used in an appropriate fashion in 
patients who have active HSP27.
Introduction
The heat shock proteins (HSPs) are ubiquitously expressed in 
almost all cells and across species. The protein family was so 
named owing to their initial discovery, namely, identified from 
cells under heat shock and is now known to be involved in a 
number of other cellular stresses including heat, carcinogens, 
mechanical and chemical stress (1,2). These proteins serve as 
molecular chaperones and act as a mechanism to assist protein 
folding, repair damaged proteins, or assist in degrading the 
unwanted proteins after stress and injury, thus by doing so 
the proteins protect the injured cells from potentially lethal 
damage (3,4). The HSP proteins are thus important regula-
tors in normal physiology, but are also involved in diseases 
including cardiovascular, wound healing and cancer.
Similarly discovered from cells under heat shock, HSP27 
has been found to be widely involved in other types of cell 
stress, including oxidative response (5-8). The HSP27 is a 
protein of approximately 27 kDa in size and belongs to the 
HSP family in which sizes vary between 8-150 kDa. The 
main cellular function of HSP27 is protecting cells from 
becoming apoptotic, or anti-apoptotic. Although this role is 
critically important in homeostasis, it has serious implica-
tions in clinical cancer. Firstly, HSP27 has been found to be 
overexpressed in a variety of human cancers and linked to a 
poor outcome for those cancer patients (9-13); secondly, high 
levels of HSP27 in cancer cells have been shown to promote 
cancer cell growth (14-16); and thirdly, HSP27 was found to 
be extremely elevated following chemotherapy, most probably 
as a protective mechanism to chemical stress (17-19). In the 
latter case, HSP27 and HSP70 were two of the gene products 
that were upregulated in a cisplatin resistant ovarian cancer 
cell line (19). Thus, this has caused an enormous challenge 
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to cancer treatment and is frequently linked to chemotherapy 
resistance in cancer.
The key mode of activation of HSP27 is by phosphoryla-
tion. Phosphorylation of HSP27 allows itself to form oligomers 
which may facilitate the chaperone process under cellular 
stress (20,21). Phospho-HSP27 interacts with other pro-
apoptotic proteins such as DAXX and ASK1 and therefore by 
blocking pro-apoptotic protein interaction blocks the apoptotic 
pathway (22,23). Other known pathways of HSP27 include 
interaction with AKT1 and the oestrogen receptor. By inter-
acting with these signalling proteins, phospho-HSP27 blocks 
some of their actions in cancer cells. The most commonly 
reported sites of phosphorylation with HSP27 are S15, S78, 
S82 and S86. Consequently, phosphorylated HSP27 protein 
levels have been found to be frequently raised in clinical 
cancer tissues and chemoresistant cancer cells (24,25).
Together, it is suggested that HSP27 is a valid target for 
cancer treatment. methods to either reduce the protein levels 
of HSP27 or the phosphorylation of HSP27, would be desirable 
in devising cancer treatment (26). A new anti-HSP27 agent, 
known as OGX427 (Apatorsen) has entered into a late phase 
clinical trial in patients with various malignant conditions 
including pancreatic, lung, bladder or prostate cancer, alone 
or in combination with other chemotherapies (27-30). Early 
studies have shown a favourable outcome from the new treat-
ment.
There have been clinical trials which have shown that 
YangZheng XiaoJi (YZXJ), a combination of traditional 
Chinese medicinal herbs benefit cancer patients; however, how 
this mechanism of action is achieved remains unknown (31-34). 
The present study reports an accidental and surprising 
discovery that a traditional Chinese herbal medicine, known 
as YangZheng XiaoJi (YZXJ) used in treating patients with 
cancer, can suppress the phosphorylation of HSP27 and cell 
functions related to this protein.
Materials and methods
Materials. Antibodies to human HSP27 (sc-13132), caspase-3 
(sc-7148), caspase-8 (sc-70501), caspase-9 (sc-17784), phospho-
FAK (sc-81493), and GAPDH (sc-32233) were purchased from 
Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA). 
Therapeutic agents including cisplatin, topotecan, pacilitaxol 
and 5-FU were purchased from Sigma-Aldrich (Poole, Dorset, 
UK). Antibodies to FAK (ab131435) and phospho-HSP-27 (S86) 
(ab17938) were purchased from Abcam (Cambridge, UK). 
FITC/TRITC-conjugated Phalloidin and FITC- and TRITC 
conjugated secondary antibodies were from Sigma-Aldrich. 
Secondary antibodies (fluorescence- and HRT-conjugated) 
were also from Sigma-Aldrich. Anti-HSP27 siRNA, control 
siRNA and transfection reagents were also obtained from 
Santa Cruz Biotechnologies Inc.
Cells. Human gastric cancer (AGS and HGC27), pancreatic 
cancer (PANC1), ovarian cancer (SKOV3 and COV504), lung 
cancer (A549 and SKmES1), breast cancer (mDA mB-231), 
prostate cancer (PC-3) cells were purchased from LGC 
Standard/ATCC (Southampton, UK). Ovarian cancer cells 
A2780 and its cisplatin resistant strain A2780/CP70 were gifts 
from Imperial College London (Dr Euan Stronach).
YangZheng XiaoJi extracts. An extract from YZXJ, named 
DmE25 was prepared using a DmSO based method that has 
been described in full (35,36). The herbal medicinal formula, 
YangZheng XiaoJi was obtained from Yiling Pharmaceuticals 
(Shijiazhuang, HeBei, China). The formula contained 
the following 16 ingredients: Panax ginseng C.A. Mey, 
Astragalus memebranaceus (Fisch.) Bge.var. mongholicus 
(Bge.) Hsiao, Ligustrum lucidum Ait, Curcuma phaeocaulis 
Val, Ganodema lucidum, Gynostemma pentaphylla (Thunb) 
Mak, Atractylodes macrocephala Koidz, Scutellaria 
barbata D.Don, Oldenlandia diffusa (willd.) Roxb, Poria 
cocos, Duchesnea indica Focke, Solanum lyratum Thunb, 
Artemisia scoparia (Bge.) Ki, Cynanchum paniculatum Kitag, 
Eupolyphaga sinensis Walker, and Gallus domesticus Brisson. 
For experimental use, the extract was diluted in the respective 
cell culture media and the dilution range was between 1:100 
to 1:2,000.
Immunofluorescent staining. Cells, plated with test agents in 
8-well chamber slides, were first fixed using 4% formalin, 
lightly permeabilised with 0.1% Triton X100 for 5 min and 
blocked with a Tris buffer (25 mm, pH 8.4) that contained 
7.5% pre-immuned goat serum for 1 h. Primary antibodies 
(including anti-HSP27, anti-phospho-HSP27 (S86), anti-
caspases), diluted in the blocking buffer was added to the 
respective slides which were kept in the dark at full humidity 
on a slow moving platform for 1 h, and then washed thor-
oughly. FITC-tagged secondary antibodies were then added. 
After 1 h, the slides were washed thoroughly and mounted 
using FluorSave™ (Calbiochem, Nottingham, UK). TRITC-
conjugated phalloidin was diluted at final concentration of 
10 µg/ml and added to the cells together with the secondary 
antibodies. The slides were examined on an Olympus micro-
scope and photographed using a Hamamatsu digital camera. 
The staining intensity was determined using ImageJ software.
Knockdown of HSP27. Cells at approximate 70% confluence 
were rinsed with BSS buffer. Anti-HSP27 siRNA, diluted in 
RNA free water was first mixed with a transfection reagent 
and left at room temperature for 30 min before being added to 
the cells. After 7 h medium was replaced and cells were left 
to incubate for another 24 h. Expression of HSP27 was tested 
using RT-PCR.
Cell growth assay. Cancer cells were first seeded in 96-well 
tissue culture plates and allowed to adhere. The test materials 
and their combinations were then added to the cells, which were 
subsequently incubated for a period of 72 h. After removing the 
culture media, cells were fixed with 4% formalin and stained 
with 0.5% Crystal violet. After extensive washing, the staining 
was extracted with 10% acetic acid and plates were read on 
a multiple channel plate reader at 540 nm (Elx800; Bio-Tek, 
Swindon, UK). The test regimens included chemotherapeutic 
agent alone, DmE25 alone, DmE25 and chemotherapeutic 
agent combination and DmE25 pre-treatment followed by 
chemotherapeutic agent.
Protein arrays for detecting phosphorylation changes. Cancer 
cells at 90% confluence in two T75 tissue culture flasks were 
washed with BSS buffer and then placed into a fresh batch 
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of DMEM supplemented with 5% FCS. After 5 h, treatment 
was added, again in 5% FCS. After a 5-h period, cells were 
removed from the flasks with a cell scraper. The cells were 
pelleted using a centrifuge at 2,500 rpm for 5 min. Lysis buffer 
was added to the cell pellets and placed on a spinning wheel for 
1 h at 4˚C. The lysates were then spun at 12,000 x g for 10 min 
at 4˚C. The supernatants were carefully collected and the 
insolubles discarded. Based on absorbance the protein concen-
tration in the cell lysates were quantified using the scatter line 
chart of microsoft Excel and then adjusted to 2 mg/ml. The 
samples were stored at -20˚C until use. Antibody based protein 
arrays, namely KAm850, which has 854 capture antibodies 
spotted on to each array slides (Kinexus Bioinformatics 
Ltd., Vancouver, Canada) were used in the present study. 
The following are the key parameters collected and used 
for the data analysis: Globally Normalized Signal Intensity, 
Background corrected intensity values are globally normal-
ized. The Globally Normalized Signal Intensity was calculated 
by summing the intensities of all the net signal median values 
for a sample. Z Scores, Z score transformation corrects data 
internally within a single sample. Z Score Difference, The 
difference between the observed protein Z scores in samples 
in comparison. Z Ratios, Divide the Z Score Differences by 
the SD of all the differences for the comparison.
Electric cell-substrate impedance sensing (ECIS) based 
analyses on cell adhesion and cell migration. Briefly, 96-well 
W96E1 microarrays were used on the ECIS Ztheta instrument 
(Applied Biophysics Ltd., Troy, NJ, USA). Lung cancer cells 
were added to the wells of the array, followed by immediate 
tracking of cell adhesion over a range of frequencies (1,000 
to 64,000 Hz) using automated modules. The adhesion was 
analysed using the mathematical modelling methods as previ-
ously described. For cellular migration, confluent lung cancer 
monolayers in the arrays were electrically wounded (2,000 mA 
for 20 sec each), after which the migration of the cells was 
immediately tracked, again over a range of frequencies. All the 
experiments were conducted in triplicate.
Western blotting analysis of HSP27 proteins. Proteins, 
prepared in a similar fashion to that for protein analysis, 
were separated on a SDS-PAGE genes, following transfer of 
Figure 1. (A) Detection of HSP27 and phospho-HSP27 in SKmES1 lung cancer cells after treatment with DmE-25 a YZXJ extract. (B) Changes in HSP27 and 
phospho-HSP27 in PANC-1 pancreatic cancer cells after treatment with DmE-25 a YZXJ extract.
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proteins to nitrocellulose membranes, the membranes were 
probed with the respective antibodies in a set protocol that 
including extensive washings in between the antibody probing 
and finally detecting the antibody signals using chemillumi-
nescence reagents. The membranes were visualised using an 
imager (G-Box; Syngene, Cambridge, UK).
Results
DME25 has a marked effect on the phosphorylation of HSP27. 
Using a protein array, we found that the YZXJ extract DmE25 
resulted in a marked reduction of phosphorylation of HSP27, 
particularly on Serine86 (S86) phosphorylation, in SKmES-1 
lung cancer and PANC-1 pancreatic cancer cells (Fig. 1A and 
B, respectively).
Localisation of HSP27 and phospho-HSP27 (S86) in cancer 
cells, assessed by immunofluorescence. HSP27 was seen 
broadly in the nucleus and in cytoplasmic region of lung cancer 
cells (Fig. 2A, top panel). It is very interesting to note that 
both total HSP27 and phospho-HSP27 was localised in focal 
adhesion and pseudopodia regions of the cells. Treatment of 
the lung cancer cells, SKmES1 with DmE25 resulted in loss 
of phospho-HSP27 from the focal adhesion and pseudopodia 
Figure 2. (A) Staining of phosphorylated HSP27 (S86) in SKmES1 human lung cancer cells (top panel) and pancreatic cancer PANC1 (bottom) after treat-
ment with DmE-25. In the control, phospho-HSP27 was seen predominantly in the focal adhesion complex regions (white arrows). Treatment with YZXJ 
extract DmE25 resulted in almost complete loss of phospho-HSP27 from the focal adhesion complex (pink arrows). (B) Effects of DmE-25 on HSP27 and its 
activation in SKmES1 cells as shown by western blotting. (C) Effects of DmE-25 on HSP27 and its activation in PANC1 cells as shown by western blotting.
Table I. Effects of cisplatin on the growth of cancer cells in combination with DmE25.
 16 ng/ml 400 ng/ml 10 µg/ml ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------
Cisplatin Control YZXJ Control YZXJ Control YZXJ
AGS   7.9±2.5   9.1±0.7 20.8±2.0 14.5±2.6 93.1±0.5 91.5±0.5
mIAPACA2 50.1±4.5 92.1±1.5 77.5±1.5 93.1±4.4 77.8±2.5 93.2±2.6
A549 20.1±1.7 12.2±2.7 50.4±1.3 44.1±1.7 90.4±0.4 89.9±0.2
SKmES1   1.7±0.3 34.6±1.7 23.0±1.4 46.3±2.0 80.5±3.5 86.9±2.6
COV504 NC   3.8±6.2 27.2±4.7 43.4±2.7 74.6±2.8 85.1±1.3
SKOV3 NC 17.2±1.9   0.5±1.5   9.8±2.6 46.7±1.5 66.7±2.7
NC, negative control.
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regions of the cells, although the changes of total HSP27 did 
not appear to differ (Fig. 2). The same changes of phospho-
HSP27 were seen in pancreatic cancer cells, PANC1 (Fig. 2A, 
bottom panel) as well as in ovarian cancer cell SKOV3 and 
gastric cancer AGS cells (data not shown). The inhibition 
on levels and activation of HSP27 was also demonstrated by 
western blotting analysis in both the lung and pancreatic cells 
(Fig. 2B and C, respectively).
Activated HSP27 is co-localised with caspase-9 in cancer 
cells, which is prevented when cells are treated with DME25. 
When co-stained for phospho-HSP27 (S86) and caspase-9, it 
was found that both molecules co-localised in regions of focal 
adhesion (FAC) and pseudopodia (Fig. 3A and B). It was very 
interesting to note that when cells were treated with DmE25, 
this pattern of co-localisation appears to break (Fig. 3B).
Phospho-HSP27 and its co-localisation with filamentous actin 
and caspase-9 in cancer cells and in chemoresistant cancer 
cells. Using dual fluorescence staining, we have shown that 
phospho-HSP27 and F-actin did co-localise in FAC regions 
in both wild-type ovarian cancer A2780 (Fig. 4A, top panels) 
and in cisplatin resistant A2780/CP70 cells (Fig. 4 bottom 
panels). The same was seen with lung cancer cells (Fig. 5). In 
all the cells tested, treatment with DmE25 reduced the loca-
tion of phospho-HSP27 to the FAC region. The co-localisation 
Figure 3. (A) Co-staining phospho-HSP27 and caspase-9 in human lung cancer SKmES-1 cells. Control cells displayed high levels of staining of both phospho-
HSP27 and caspase-9, both also showing a high degree of co-localisation (white arrows). However, the co-localisation was eliminated by DmE25 (bottom 
images). (B) Images under a higher power showing focal adhesion (FAC) and pseudopodia within the SKmES-1 cells.
Figure 4. (A) Co-staining phospho-HSP27 and phalloidin in human wild-type ovarian cancer A2780 (top panel) and A2780-CP70 (bottom panel) cells. (B) The 
co-localisation between phospho-HSP27 and caspase-9 was shown in the respective two cell lines A2780 (top panel) and A2780-CP70 (bottom panel). DmE25 
is the extract from YZXJ.
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of phospho-HSP27 and caspase-9 in wild-type A2780 and 
cisplatin resistant A2780/CP70 were also reduced in the pres-
ence of DmE25 (Fig. 4B).
Effect of DME25 on the growth of ovarian cancer cells. A2780/
CP70 showed approximately 8 times less sensitivity to cisplatin 
compared with the wild-type parental cells (Fig. 6). Co-culture 
of both cisplatin and DmE25 resulted in the cells becoming 
more sensitive to cisplatin, as seen for lung, gastric, pancreatic 
and ovarian cancer cells (Tables I-V). However, knocking down 
HSP27 by siRNA did not significantly influence the sensitivity 
of the cells to the chemotherapeutic agents (data not shown).
HSP27 shows marked influence on cell migration and 
acts synergistically with YangZheng XiaoJi on cancer cell 
migration. In light of the co-localisation of HSP27 and phal-
loidin at the focal adhesion regions of cancer cells and our 
previous reports on the impact of DmE25 on the migration 
of various cells including cancer cells, we tested how HSP27 
might affect cell migration. It was readily demonstrable that 
knocking down HSP27 resulted in a sustained reduction of 
cell migration (Fig. 7A and B). It was further confirmed that 
knocking down HSP27 increased sensitivity of cancer cells to 
low dosage chemotherapeutic agents and in particular when 
DmE25 was present (Fig. 7C and D).
Discussion
The current study stemmed from a surprising finding in 
our search for the potential pathways that are influenced by 
Figure 5. Co-staining phospho-HSP27 and Phalloidin in human lung cancer SKmES-1 cells.
Table II. Effects of pacilitaxel on the growth of cancer cells in combination with DmE25.
 3.2 ng/ml 80 ng/ml 2 µg/ml ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------
Pacilitaxel Control YZXJ Control YZXJ Control YZXJ
AGS 42.3±0.3 45.2±2.2 61.9±0.9 63.4±2.6 64.6±1.0 64.9±0.2
mIAPACA2 47.0±2.5 89.3±2.8 75.6±2.6 91.6±2.1 73.6±2.0 91.0±5.1
A549 46.3±0.7 51.7±0.8 66.2±1.0 66.2±1.3 69.7±1.7 69.2±1.7
SKmES1 20.0±2.4 62.4±7.3 55.7±2.3 78.3±3.0 63.2±1.9 74.8±3.6
COV504 38.7±2.7 64.4±0.9 57.2±0.6 74.1±1.7 55.6±0.9 74.2±1.0
SKOV3 34.2±1.6 59.5±2.7 40.0±1.1 66.6±2.4 49.6±1.6 66.0±3.5
Figure 6. Wild-type A2780 and cisplatin resistance A2780/CP70 responded 
differently to cisplatin.
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DmE25, a traditional Chinese medicinal formula used in 
cancer treatment.
HSP27, YangZheng XiaoJi and sensitivity to chemotherapeutic 
agents. The role of HSP27 in the sensitivity to chemotherapy 
agents is not without controversy. For example, it has been 
reported recently that overexpression of HSP27 in pancreatic 
cancer cells would increase the sensitivity of the cancer cells 
to gemcitabine (37). Although reasons for this are not clear, 
the type of drugs used in the study may be an explanation, as 
these drugs are transported and act in cancer cells via different 
mechanisms.
HSP27 acts as a cyto-protective molecule during androgen 
independence in prostate cancer patients and in prostate 
cancer cell models (38). Likewise, levels of HSP27 correlated 
with resistance to irinotecan in colorectal cancer cells (39). 
HSP27, together with HSP70 is linked to the sensitivity of 
colorectal cancer to the naturally-occurring anticancer agent 
curcumin (40).
Knocking down HSP27 sensitises glioblastoma multiforme 
tumour cells to the HSP90 inhibitor, 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) and staurosporine by 
changes in apoptosis (41). The same was seen in glioma cells, 
in that silencing HSP27 resulted in an increase in apoptosis in 
response to temozolomide and quercetin (42).
HSP27, YangZheng XiaoJi and cell migration. The finding that 
HSP27 is co-localised with phalloidin to the focal adhesion 
Figure 7. (A and B) Effects of knocking down HSP27 on the migration of SKmES1 cells. (C) The knockdown also increased the sensitivity of cancer cells 
to low concentration of drugs, in particular when combined with DmE25. (D) Effects of knocking down HSP27 on the migration of PANC-1 cells which is 
further decreased in the presence of DmE25.
Table III. Effects of 5-FU on the growth of cancer cells in combination with DmE25.
 1.6 µg/ml 40 µg/ml 1000 µg/ml --------------------------------------------------- ------------------------------------------------------------- --------------------------------------------------
5-FU Control YZXJ Control YZXJ Control YZXJ
AGS 13.1±1.6   3.6±1.8 59.6±0.8 56.8±1.6 79.2±0.6 75.3±2.1
mIAPACA2 NC 57.8±1.5 33.4±5.9 70.8±3.2 64.4±3.5 88.6±7.8
A549 15.0±3.1 12.7±4.1 59.2±2.0 57.6±3.5 70.3±1.8 69.9±2.1
SKmES1 10.5±2.3 29.0±1.4 51.9±3.4 65.0±1.3 57.5±2.6 68.2±2.1
COV504 15.6±1.4 48.2±1.6 40.5±2.4 59.1±2.6 50.4±0.9 63.7±1.6
SKOV3 10.4±0.8 20.9±2.8 32.7±43.5±0.9 43.9±1.9 46.0±1.8 60.9±1.4
NC, negative control.
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regions of cancer cells is interesting. From the immunofluores-
cence staining, HSP27 particularly the phosphorylated form 
of the protein, is frequently co-localised with Phallodin at 
the focal adhesion regions of cancer cells, where caspase-9 
is also seen. It is of interest to note that inclusion of YZXJ 
extract DmE25 in the study markedly reduce the presence of 
phospho-HSP27 (S86) at the focal adhesions. Given the key 
role of focal adhesion in cell-matrix adhesion and cellular 
migration, it is plausible to suggest that activation of HSP27 
(by way of phosphorylation) coordinates with other proteins in 
the focal adhesion area, such as integrins and the focal adhe-
sion kinase (FAK) to regulate the adhesion and migration of 
cancer cells. We have recently reported that YZXJ was able 
to inhibit the phosphorylation of FAK in cancer cells and in 
endothelial cells (35,43).
Together with the finding that knocking down HSP27 
resulted in an increase in cellular migration in cancer cells, 
it is suggested that HSP27, in particular when combined with 
YZXJ, is an important regulator of EmT reversal or mET. It 
has been reported recently that HSP27 is key to IL-6 dependent 
and IL-6 independent EmT in prostate cancer cells, by acting 
on IL-6 induced activation of STAT3/Twist and Snail (44,45). 
It is also involved in EGF induced EmT in prostate cancer 
cells by influencing the migration of these cells (46,47). Other 
than the reported effects on cancer cells, HSP27 has also been 
shown to be a mediator for angiogenesis (48), suggesting that 
HSP27 is involved in a wider range of processes in cancer 
development and progression.
Taken together, it is clear that HSP27 is a viable target in 
cancer treatment and that a combined approach, with either 
YZXJ or another method, would be a valid consideration when 
devising a therapy in either targeting HSP27 or in certain 
chemoresistance cases.
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